PLDN(pallidin)失调是RUNX1单倍剂量不足导致血小板致密颗粒缺陷的机制
RUNX1单倍剂量不足患者血小板致密颗粒缺陷的分子机制未知。研究通过血小板mRNA表达谱发现PLDN(BLOC1S6)表达降低,并在体外实验中证实RUNX1直接结合PLDN启动子调控其表达,PLDN下调导致致密颗粒形成受损,为RUNX1单倍剂量不足相关致密颗粒缺陷提供机制证据。
要点
- RUNX1单倍剂量不足患者血小板中pallidin和致密颗粒水平降低
- RUNX1直接结合PLDN启动子并调控其转录活性
- PLDN下调导致HEL细胞致密颗粒形成受损
核心结论
- PLDN是RUNX1的直接靶基因,其失调是RUNX1单倍剂量不足相关血小板致密颗粒缺陷的机制。
研究设计与样本
- 研究纳入先前报道的1例RUNX1突变伴血小板功能障碍患者及另一家系的2例同胞,并进行体外细胞实验。
主要发现
- 患者血小板中pallidin和致密颗粒水平降低,另一家系2例RUNX1突变同胞也观察到同样现象。
- 染色质免疫沉淀和电泳迁移率变动分析显示RUNX1结合于PLDN1 5'上游区域的RUNX1共识位点。
- 荧光素酶报告基因研究中,PLDN启动子RUNX1位点突变降低活性。
- RUNX1过表达增强而RUNX1下调降低PLDN1启动子活性和蛋白表达。
- RUNX1下调导致HEL细胞中mepacrine处理受损及致密颗粒标志物CD63错误定位,表明致密颗粒形成受损。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Platelet dense granule (DG) deficiency is a major abnormality in RUNX1 haplodeficiency patients. The molecular mechanisms leading to the platelet DG deficiency are unknown. Platelet expression of PLDN (BLOC1S6, pallidin), involved in DG biogenesis, is regulated by RUNX1. Downregulation of PLDN is a mechanism for DG deficiency in RUNX1 haplodeficiency. SUMMARY: Background Inherited RUNX1 haplodeficiency is associated with thrombocytopenia and platelet dysfunction. Dense granule (DG) deficiency has been reported in patients with RUNX1 haplodeficiency, but the molecular mechanisms are unknown. Platelet mRNA expression profiling in a patient previously reported by us with a RUNX1 mutation and platelet dysfunction showed decreased expression of PLDN (BLOC1S6), which encodes pallidin, a subunit of biogenesis of lysosome-related organelles complex-1 (BLOC-1) involved in DG biogenesis. PLDN mutations in the pallid mouse and Hermansky-Pudlak syndrome-9 are associated with platelet DG deficiency. Objectives We postulated that PLDN is a RUNX1 target, and that its decreased expression leads to platelet DG deficiency in RUNX1 haplodeficiency. Results Platelet pallidin and DG levels were decreased in our patient. This was also observed in two siblings from a different family with a RUNX1 mutation. Chromatin immunoprecipitation and electrophoretic mobility shift assays with phorbol ester-treated human erythroleukemia (HEL) cells showed RUNX1 binding to RUNX1 consensus sites in the PLDN1 5' upstream region. In luciferase reporter studies, mutation of RUNX1 sites in the PLDN promoter reduced activity. RUNX1 overexpression enhanced and RUNX1 downregulation decreased PLDN1 promoter activity and protein expression. RUNX1 downregulation resulted in impaired handling of mepacrine and mislocalization of the DG marker CD63 in HEL cells, indicating impaired DG formation, recapitulating findings on PLDN downregulation. Conclusions These studies provide the first evidence that PLDN is a direct target of RUNX1 and that its dysregulation is a mechanism for platelet DG deficiency associated with RUNX1 haplodeficiency.
引用
- Mao GF, Goldfinger LE, Fan DC, et al. Dysregulation of PLDN (pallidin) is a mechanism for platelet dense granule deficiency in RUNX1 haplodeficiency. J Thromb Haemost. 2017. PMID: 28075530. doi:10.1111/jth.13619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。